Movatterモバイル変換


[0]ホーム

URL:


Jump to content
WikipediaThe Free Encyclopedia
Search

Yohimbine

From Wikipedia, the free encyclopedia
"Yoman" redirects here. For the film called "Yoman" in Hebrew, seeDiary (1983 film).
This article is about the chemical compound. For the plant and its medicinal bark preparation, seeyohimbe.
Chemical compound
Pharmaceutical compound
Yohimbine
Clinical data
Pronunciation/jˈhɪmbn/[1]
Other namesQuebrachine
Routes of
administration
By mouth
Drug classα2-Adrenergic receptorantagonist
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability7-86% (mean 33%)
Eliminationhalf-life0.25–2.5 hours[2]
ExcretionUrine (as metabolites)
Identifiers
  • 17α-hydroxyyohimban-16α-carboxylic acid methyl ester
CAS Number
PubChemCID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard(EPA)
ECHA InfoCard100.005.157Edit this at Wikidata
Chemical and physical data
FormulaC21H26N2O3
Molar mass354.450 g·mol−1
3D model (JSmol)
  • [H][C@@]15CC[C@H](O)[C@H](C(=O)OC)[C@@]1([H])C[C@@]4([H])c3[nH]c2ccccc2c3CCN4C5
  • InChI=1S/C21H26N2O3/c1-26-21(25)19-15-10-17-20-14(13-4-2-3-5-16(13)22-20)8-9-23(17)11-12(15)6-7-18(19)24/h2-5,12,15,17-19,22,24H,6-11H2,1H3/t12-,15-,17-,18-,19+/m0/s1 checkY
  • Key:BLGXFZZNTVWLAY-SCYLSFHTSA-N checkY
  (verify)

Yohimbine, also known asquebrachine, is anindolealkaloid derived from the bark of the African treePausinystalia johimbe (yohimbe) and from the bark of the unrelated South American treeAspidosperma quebracho-blanco.[3][4] It is a veterinary drug used to reverse sedation in dogs and deer.

Substances that have purported to beextracts from the yohimbe tree have been marketed asdietary supplements for various purposes, but they contain highly variable amounts of yohimbine, if any; no publishedscientific evidence supports their efficacy for treating sexual dysfunction or any disease.[3][4][5]

Uses

[edit]

Sexual dysfunction and aphrodisiac

[edit]

There is no evidence from randomized, placebo-controlled trials that yohimbine is effective as an aphrodisiac, for treating sexual dysfunction, or for any health condition.[3][4]

Yohimbine has been used to treatfemale sexual dysfunction, but there are few reported clinical trials and these do not show it to be better than placebo.[6][7][8][9]

Yohimbine has been largely superseded by thePDE5 inhibitor drugs such assildenafil (Viagra). Prescriptions for it are now rare, and most United States pharmaceutical manufacturers have discontinued production of prescription capsules and tablets.[10]: 357–8 

In the United States, "yohimbe" preparations are sold as a dietary supplements for enhancinglibido, for weight loss and as aids for bodybuilding; but "There is virtually no published research on yohimbe which supports these or any other claims".[8]: 861  Often, these products explicitly claim to contain yohimbine.[10]

One study found that samples of brands sold in American brick-and-mortar stores contained highly variable amounts of yohimbine, and sometimes none at all.[10]: 368  Labelling claims were often misleading.[10]: 368  Similar results have been reported by other laboratories for products sold in the US, in other countries and on the internet.[11][12][13][14][15] One study found that many brands of "yohimbe" might not derive from theP. johimbe tree in the first place.[16] According to yet another source, the yohimbe sold in markets in West Africa, where the tree grows, is frequently adulterated with other species of the genusPausinystalia; these contain little yohimbine.[17] The amounts of alkaloid found even in genuineP. johimbe bark vary considerably, depending on the source of the bark (roots, stem, branches, height, etc.).[18]

Some brands sold over-the-counter were found to contain more yohimbine per serving than a standard pharmaceutical dose.[10]: 368  It is illegal to introduce or deliver "drugs" into interstate commerce without the permission of the USFood and Drug Administration (FDA). The FDA has asserted that some yohimbine-containing products are "drugs" because they are so promoted as to show "they are intended for use in the cure, mitigation, treatment or prevention of disease": 21 U.S.C. § 321(g)(1)(B).[19] However the legal position is not entirely straightforward,[20] and as of 1 February 2019 there does not appear to be any record of a successful prosecution.

Because of the lack of reliable scientific data on yohimbe, the European Food Safety Authority Panel on Food Additives determined that it was not possible to conclude on its safety or to establish a health-based guidance value.[5]: 38  They wrote:

Overall the missing information include[s] quantitative data on the composition and specifications of yohimbe bark and its preparations used in food and food supplements covering other alkaloids besides yohimbine, data on the bioavailability of active ingredients from the yohimbe bark extract and data on the toxicity of well specified individual preparations of yohimbe bark and the major yohimbe bark alkaloids, especially regarding subchronic toxicity, genotoxicity and reproductive toxicity.

It has been studied as a potential treatment forerectile dysfunction, but there is insufficient evidence to rate its effectiveness.[21][22][23] It is illegal in the United States to market an over-the-counter product containing yohimbine as a treatment for erectile dysfunction without getting FDA approval to do so.[24] Nevertheless, the quantity of yohimbine in dietary supplements, often advertised as promoting sexual function, has been found to overlap with prescription doses of yohimbine.[25]

Other uses

[edit]

Yohimbine has been used to increase peripheral blood flow and to dilate the pupil of the eye[26]

Side effects

[edit]

Side effects of yohimbine in humans at high doses includehypertension (high blood pressure),tachycardia (rapid heartbeat),agitation,hypervigilance,anxiety,tremors,nausea andurinary frequency.[3][4][27][28][29] The drug is described as producing apsychoactive state of considerable anxiety along withtenseness,restlessness, andirritability and as being "extremely unpleasant", at least at the assessed doses.[30] In animals, yohimbine likewise produces effects suggestive of severe anxiety.[30] Yohimbine has been used in animals as a model of anxiety in the evaluation of novelanxiolytics.[30]

Interactions

[edit]

Barbiturates andbenzodiazepines can reduce theanxiety produced by yohimbine.[30] Conversely, combination withimipramine, which is notably known to act as anorepinephrine reuptake inhibitor, has been reported to augment therestlessness and anxiety of yohimbine and to convert them intopanic.[30]

Pharmacology

[edit]

Yohimbine has highaffinity for theα2-adrenergic receptor, moderate affinity for theα1 receptor,5-HT1A,5-HT1B,5-HT1D,5-HT1F,5-HT2B, and dopamineD2 receptors, and weak affinity for the5-HT1E,5-HT2A,5-HT5A,5-HT7, and dopamineD3 receptors.[31][32] It behaves as anantagonist at α1-adrenergic, α2-adrenergic, 5-HT1B, 5-HT1D, 5-HT2A, 5-HT2B, and dopamine D2, and as apartial agonist at 5-HT1A.[31][33][34][35] Yohimbine interacts with serotonin and dopamine receptors in high concentrations.[36]

Pharmacologic profile
Molecular targetBinding affinity
(Ki innanomolar)[32]
Pharmacologic action
[31][33][34][35][37][38]
SpeciesSource
SERT1,000InhibitorHumanFrontal cortex
5-HT1A346Partial agonistHumanCloned
5-HT1B19.9AntagonistHumanCloned
5-HT1D44.3AntagonistHumanCloned
5-HT1E1,264UnknownHumanCloned
5-HT1F91.6UnknownHumanCloned
5-HT2A1,822AntagonistHumanCloned
5-HT2B43–143.7AntagonistHumanCloned
5-HT72,850UnknownHumanCloned
α1A1,680AntagonistHumanCloned
α1B1,280AntagonistHumanCloned
α1C770AntagonistHumanCloned
α1D557AntagonistHumanCloned
α2A1.05AntagonistHumanCloned
α2B1.19AntagonistHumanCloned
α2C1.19AntagonistHumanCloned
D2339AntagonistHumanCloned
D33,235AntagonistHumanCloned

Yohimbine selectively blocks the pre-synapticα2-adrenergic receptors. Blockade of post-synaptic α2-adrenergic receptors causes only minorcorpus cavernosumsmooth muscle relaxation, due to the fact that the majority ofadrenoceptors in the corpus cavernosum are of the α1 type. Blockade of pre-synaptic α2-adrenergic receptors facilitates the release of several neurotransmitters in the central and peripheralnervous system—thus in the corpus cavernosum—such asnitric oxide andnorepinephrine. Whereas nitric oxide released in the corpus cavernosum is the major vasodilator contributing to the erectile process, norepinephrine is the major vasoconstrictor through stimulation ofα1-adrenergic receptors on the corpus cavernosum smooth muscle. Under physiologic conditions, however, nitric oxide attenuates norepinephrine vasoconstriction.[39]

Yohimbine binds to the a2 adrenergic receptor at a ratio of 40:1 and is the only a2 adrenergic receptor antagonist with noimidazoline receptor activity.[40]

Chemistry

[edit]

Yohimbine is apolycycliccyclized tryptamine andyohimbanderivative.

Related compounds

[edit]

Other related compounds includeajmalicine,alstonine,corynanthine,deserpidine,mitragynine,rauwolscine,spegatrine,reserpine, andrescinnamine.

Natural occurrence

[edit]

Pausinystalia johimbe

[edit]

Yohimbine should not be confused withyohimbe[41] but often is.[42] Yohimbe is the common English name for the tree speciesP. johimbe (also calledCorynanthe johimbe) and, by extension, the name of a medicinal preparation made from the bark of that tree, sold as anaphrodisiac.[43] In contrast, yohimbine is a pure alkaloid that can be isolated from yohimbe bark.

Yohimbine is just one of at least 55 indole alkaloids that have been isolated from the bark;[44] and, while it has been described as the most active of these,[10] it constitutes only 15% of the total alkaloid content.[8] Others includerauwolscine,corynanthine andajmalicine;[8] the bark also contains non-alkaloids about which virtually nothing is known.[8]

Yohimbe, thus a complex mixture, has been studied far less thoroughly than yohimbine, the pure compound.[8] Pharmaceutical grade yohimbine is usually presented as thehydrochloride,[5][8] which is more soluble.

The traditional source of yohimbine is the bark of the African treeP. johimbe. It has other uses, but the tree is sought out primarily for its bark; in practice, harvesting the bark kills the tree. Tree density is relatively low (average ≈ 4 harvestable trees/hectare). The high demand for medicines based on the bark has led to the tree's over-exploitation. The bark is traded in local markets and, because it is scarce, it is often adulterated with that of other species which contain little yohimbine.[17] The species is becoming endangered.[45]

Around the year 2000,Cameroon was shippingP. johimbe to Europe at the rate of about 100 tonnes annually. Most bark is collected illegally by local people who are paid 150CFA francs per kilo (about US$0.10 per pound) for delivery of pre-dried bark at the roadside. In practice they confuse and mix it withP. macroceras ("false yohimbe"), a species that contains little yohimbine.[46]

Aspidosperma quebracho-blanco

[edit]

Aspidosperma quebracho-blanco is an unrelated tree whose common name isquebracho blanco.[47] It is found in large areas of central South America, particularly theGran Chaco, where it is often the dominant species in thecanopy.[48] It is one of the most widely distributed Argentine arboreal species.[49][50] Traditionally it was logged for fuel, timber and railway sleepers.[50] While in recent times cattle ranching and soya cultivation have led to considerable habitat loss,[51] and while there is stillillegal logging, no shortage of the bark is reported. The tree has not been described as endangered: a few members of the genusAspidosperma are on theIUCN Red List. but thequebracho blanco species is not one of them.[52]

In its bark an alkaloid is found which was given the name quebrachine. In 1914, two scientific papers claimed quebrachine was chemically identical to yohimbine.[53] This was disputed,[54] and the matter long remained in doubt.[55] However, in 1972, Effler and Effler using modern analytical techniques, includingmass spectrometry,UV absorption,IR absorption, andNMR, established that quebrachine and yohimbine are one and the same thing. They wrote:

While it was almost unthinkable in 1914 ... that the same alkaloid was formed in [completely] different plants, recent studies have shown that this is certainly the case for indole alkaloids.[56]

A range of secondary reference works give 'quebrachine' as a synonym for yohimbine.[57][58][59][60][61][62][63][64][65]

Strictly speaking, wroteGeorge Barger, yohimbine should have been given the scientific namequebrachine, seeing that it was first isolated from the quebracho tree and first named in the scientific literature. However the later work onP. yohimbe was better known, so the newer name stuck.[53]

Other plants

[edit]

Yohimbine has also been isolated from other plant genera in the familyApocynaceae includingLochnera (Catharanthus),[66]Rauvolfia,Amsonia,Vallesia andVinca; from the familyLoganiaceae (generaGelsemium andStrychnos); and from the familyEuphorbiaceae (genusAlchornea).[8]

History

[edit]

Yohimbe (Pausinystalia johimbe) is a tree that grows in western and centralAfrica;[67] yohimbine was named as originally extracted from the bark of yohimbe in 1896 by Adolph Spiegel[68] (but see§ Aspidosperma quebracho-blanco below). Yohimbe is used in folk medicine as anaphrodisiac. In 1900, it attracted scientific interest in Germany, where an initial report claimed that yohimbe exerted a strong aphrodisiacal effect in animals and humans.[8] Attention soon shifted from the plant to its active constituents, particularly yohimbine.[8] In 1943 the correct constitution of yohimbine was proposed by Witkop.[69] Fifteen years later, a team led byEugene van Tamelen used a 23-step synthesis to become the first persons to achieve the synthesis of yohimbine.[70][71][72]

Society and culture

[edit]

Doping in sport

[edit]

There was a case in theWorld Anti-Doping Agency practice in 2007, when an athlete, who reportedly consumed Yohimbine prior to a given athletic event, was later tested positive for19-norandrosterone, which is a prohibited substance.[73] However, WADA did not yet list Yohimbine (which can come into a body via anenergy drink,[74] also in a form ofpre-workout supplement orfat burner[75]) as aprohibited substance, nor did it confirm that its use can increase the endogenous level of anabolic steroids, in particular of 19-norandrostenedione and testosterone.

Research

[edit]

Post-traumatic stress disorder

[edit]

Yohimbine has been studied as a way to improve the effects ofexposure therapy in people withpost-traumatic stress disorder (PTSD).[76][77][78]

Veterinary use

[edit]

Yohimbine has been used since the 1970s to reverse the effects of xylazine.[40] A 2011 preliminary study found thatintravenous yohimbine has slow elimination and a large distribution in horses.[40][79] Yohimbine is not commonly used in small animal medicine anymore but is still commonly used in large animal medicine to reverseα2 adrenergic receptor agonists such asxylazine.[40]

References

[edit]
  1. ^"Yohimbine. (n.d.)".Collins English Dictionary – Complete and Unabridged. (1991, 1994, 1998, 2000, 2003). Retrieved27 January 2015.
  2. ^Hedner T, Edgar B, Edvinsson L, Hedner J, Persson B, Pettersson A (1992). "Yohimbine pharmacokinetics and interaction with the sympathetic nervous system in normal volunteers".European Journal of Clinical Pharmacology.43 (6):651–6.doi:10.1007/BF02284967.PMID 1493849.S2CID 12346330.
  3. ^abcd"Yohimbe". National Center for Complementary and Integrative Health, US National Institutes of Health. April 2025. Retrieved20 June 2025.
  4. ^abcd"Yohimbe". Drugs.com. 26 June 2024. Retrieved20 June 2025.
  5. ^abcEFSA Panel on Food Additives and Nutrient Sources Added to Food,European Food Safety Authority (2013)."Scientific Opinion on the evaluation of the safety in use of Yohimbe (Pausinystalia yohimbe (K. Schum.) Pierre ex Beille)".EFSA Journal. 7.11 (7): 3302 (1–46).doi:10.2903/j.efsa.2013.3302.
  6. ^Betz, 2010, 862.
  7. ^Tam SW, Worcel M, Wyllie M (2001). "Yohimbine: a clinical review".Pharmacology and Therapeutics.91 (3): 239.doi:10.1016/S0163-7258(01)00156-5.PMID 11744068.
  8. ^abcdefghijBetz JM (2010). "Yohimbe". In Coates PM, Betz JM, Blackman MR, Cragg GM, Levine M, Moss J, White JD (eds.).Encyclopedia of Dietary Supplements (2nd ed.). New York and London: Informa Healthcare. pp. 861–3.ISBN 978-1-4398-1928-9.
  9. ^Andersson KE (December 2011). "Mechanisms of penile erection and basis for pharmacological treatment of erectile dysfunction".Pharmacological Reviews.63 (4):811–59.doi:10.1124/pr.111.004515.PMID 21880989.S2CID 6146853.
  10. ^abcdefCohen PA, Wang YH, Maller G, DeSouza R, Khan IA (2015)."Pharmaceutical quantities of yohimbine found in dietary supplements in the USA".Drug Testing and Analysis.8 (3–4):357–69.doi:10.1002/dta.1849.PMID 26391406.
  11. ^Betz JM, White KD, der Marderosian AH (1995)."Gas chromatographic determination of yohimbine in commercial yohimbe products".Journal of AOAC International.78 (5):1189–94.doi:10.1093/jaoac/78.5.1189.PMID 7549534.Concentrations of yohimbine in the commercial products ranged from < 0.1 to 489 ppm, compared with 7089 ppm in the authentic bark.
  12. ^Zanolari B, Ndjoko K, Ioset JR, Marston A, Hostettmann K (2003). "Qualitative and quantitative determination of yohimbine in authentic yohimbe bark and in commercial aphrodisiacs by HPLC-UV-API/ MS methods".Phytochemical Analysis.14 (4):193–201.Bibcode:2003PChAn..14..193Z.doi:10.1002/pca.699.PMID 12892413.Twenty commercial aphrodisiac preparations were analysed and the amount of yohimbine measured and expressed as the maximal dose per day suggested on product labels ranged from 1.32 to 23.16 mg.
  13. ^Raman V, Avula B, Galal AM, Wang YH, Khan IA (January 2013). "Microscopic and UPLC-UV-MS analyses of authentic and commercial yohimbe (Pausinystalia johimbe) bark samples".Journal of Natural Medicines.67 (1):42–50.doi:10.1007/s11418-012-0642-2.PMID 22402817.S2CID 11977944.Of 12 commercial samples tested, yohimbine was not detected in one; its presence in other samples was found to be in the range 0.1–0.91%.
  14. ^Sun J, Chen P (March 2012). "Chromatographic fingerprint analysis of yohimbe bark and related dietary supplements using UHPLC/UV/MS".Journal of Pharmaceutical and Biomedical Analysis.61:142–9.doi:10.1016/j.jpba.2011.11.013.PMID 22221902.Wide variability was observed in fingerprints and yohimbine content among yohimbe dietary supplement samples. For most of the dietary supplements, the yohimbine content was not consistent with the label claims.
  15. ^Badr JM (January 2013)."A validated high performance thin layer chromatography method for determination of yohimbine hydrochloride in pharmaceutical preparations".Pharmacognosy Magazine.9 (33):4–8.doi:10.4103/0973-1296.108124.PMC 3647393.PMID 23661986.Amount of yohimbine hydrochloride ranged from 2.3 to 5.2 mg/tablet or capsule in preparations containing the pure alkaloid, while it varied from zero to 1.5–1.8 mg/capsule in dietary supplements containing powdered yohimbe bark.
  16. ^Cohen et al, 368. (Samples did not include other alkaloids characteristic ofP. yohimbe.)
  17. ^abJiofack Tafokou RB (2012). "Pausinystalia johimbe". In Lemmens RH, Louppe D, Oteng-Amoako AA (eds.).Timbers 2 of Plant Resources of Tropical Africa. Vol. 7. Wageningen, Ne: PROTA Foundation. pp. 516–519.ISBN 978-92-9081-495-5.
  18. ^Paris R, Letouzey R (1960). "Répartition des alcaloïdes dans le Yohimbe (Pausinystalia yohimbe) (K. Schum.) ex Pierre".Journal d'Agriculture Traditionnelle et de Botanique Appliquée (in French).7 (4–5):256–258.doi:10.3406/jatba.1960.2608.
  19. ^E.g."Inspections, Compliance, Enforcement, and Criminal Investigations". US Food and Drug Administratiom. Retrieved1 February 2019.[dead link]
  20. ^"21 U.S. Code § 321 - Definitions; generally".Legal Information Institute. Cornell Law School. Retrieved1 February 2019.
  21. ^"Yohimbe Supplement". National Center for Complementary and Integrative Health. February 2007. Retrieved2017-08-28.
  22. ^Morales A (March 2000)."Yohimbine in erectile dysfunction: the facts". review.International Journal of Impotence Research.12 (Suppl 1): S70–74.doi:10.1038/sj.ijir.3900508.PMID 10845767.
  23. ^Andersson KE (September 2001). "Pharmacology of penile erection". Review.Pharmacological Reviews.53 (3):417–50.doi:10.1016/S0031-6997(24)01503-5.PMID 11546836.
  24. ^"CFR - Code of Federal Regulations Title 21: Regulations on OTC products". U.S. Food and Drug Administration. Archived fromthe original on February 8, 2004.
  25. ^Cohen PA, Wang YH, Maller G, DeSouza R, Khan IA (March 2016)."Pharmaceutical quantities of yohimbine found in dietary supplements in the USA". primary.Drug Testing and Analysis.8 (3–4):357–69.doi:10.1002/dta.1849.PMID 26391406.
  26. ^"Yohimbine (oral route) - Side effects & dosage".Mayo Clinic. Retrieved11 September 2025.
  27. ^Tam SW, Worcel M, Wyllie M (September 2001). "Yohimbine: a clinical review".Pharmacol Ther.91 (3):215–243.doi:10.1016/s0163-7258(01)00156-5.PMID 11744068.
  28. ^Biaggioni I, Robertson RM, Robertson D (May 1994). "Manipulation of norepinephrine metabolism with yohimbine in the treatment of autonomic failure".J Clin Pharmacol.34 (5):418–423.doi:10.1002/j.1552-4604.1994.tb04981.x.PMID 8089252.
  29. ^Cimolai N, Cimolai T (December 2011). "Yohimbine use for physical enhancement and its potential toxicity".J Diet Suppl.8 (4):346–354.doi:10.3109/19390211.2011.615806.PMID 22432773.
  30. ^abcdeBrimblecombe RW, Pinder RM (1975). "Indolealkylamines and Related Compounds".Hallucinogenic Agents. Bristol: Wright-Scientechnica. pp. 98–144 (118–119).ISBN 978-0-85608-011-1.OCLC 2176880.OL 4850660M. Archived fromthe original on 2025-05-27. Retrieved2025-06-14.
  31. ^abcMillan MJ, Newman-Tancredi A, Audinot V, Cussac D, Lejeune F, Nicolas JP, et al. (February 2000). "Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors. Significance for the modulation of frontocortical monoaminergic transmission and depressive states".Synapse.35 (2):79–95.doi:10.1002/(SICI)1098-2396(200002)35:2<79::AID-SYN1>3.0.CO;2-X.PMID 10611634.S2CID 20221398.
  32. ^ab"Yohimbine Test Ligand Search".PDSP Ki Database.
  33. ^abArthur JM, Casañas SJ, Raymond JR (June 1993). "Partial agonist properties of rauwolscine and yohimbine for the inhibition of adenylyl cyclase by recombinant human 5-HT1A receptors".Biochemical Pharmacology.45 (11):2337–41.doi:10.1016/0006-2952(93)90208-E.PMID 8517875.
  34. ^abKaumann AJ (June 1983). "Yohimbine and rauwolscine inhibit 5-hydroxytryptamine-induced contraction of large coronary arteries of calf through blockade of 5 HT2 receptors".Naunyn-Schmiedeberg's Archives of Pharmacology.323 (2):149–54.doi:10.1007/BF00634263.PMID 6136920.S2CID 23251900.
  35. ^abBaxter GS, Murphy OE, Blackburn TP (May 1994)."Further characterization of 5-hydroxytryptamine receptors (putative 5-HT2B) in rat stomach fundus longitudinal muscle".British Journal of Pharmacology.112 (1):323–31.doi:10.1111/j.1476-5381.1994.tb13072.x.PMC 1910288.PMID 8032658.
  36. ^"Yohimbine (PIM 567)". Inchem.org. Retrieved2013-05-26.
  37. ^"Yohimbine".DrugBank. University of Alberta. Archived fromthe original on January 30, 2013. Retrieved12 April 2014.
  38. ^Bender AM, Parr LC, Livingston WB, Lindsley CW, Merryman WD (August 2023)."2B Determined: The Future of the Serotonin Receptor 2B in Drug Discovery".J Med Chem.66 (16):11027–11039.doi:10.1021/acs.jmedchem.3c01178.PMC 11073569.PMID 37584406.
  39. ^Saenz de Tejada I, Kim NN, Goldstein I, Traish AM (March 2000)."Regulation of pre-synaptic alpha adrenergic activity in the corpus cavernosum". Review.International Journal of Impotence Research.12 (Suppl 1): S20–25.doi:10.1038/sj.ijir.3900500.PMID 10845761.
  40. ^abcdLamont LA, Creighton CM (11 September 2024). "Sedatives and Tranquilizers". In Lamont L, Grimm K, Robertson S, Love L, Schroeder C (eds.).Veterinary Anesthesia and Analgesia, The 6th Edition of Lumb and Jones. Wiley Blackwell. pp. 338–344.ISBN 978-1-119-83027-6.
  41. ^Jeske AH, ed. (2013).Mosby's Dental Drug Reference - E-Book (11th ed.). Elsevier Health Sciences.ISBN 978-0-323-17226-4., Appendix H, e83;
  42. ^Holt S, Atkins RC, Krueger RJ, Sinatra ST, Taylor T (1999).The sexual revolution: natural and healthy alternatives to sex. ProMotion Pub. p. 105.ISBN 978-1-57901-040-9.
  43. ^Oxford English Dictionary Online, article "Yohimbe", senses 1 and 2, respectively;Merriam-Webster Online, article "Yohimbe", first and second senses, respectively.
  44. ^Sun J, Baker A, Chen P (September 2011). "Profiling the indole alkaloids in yohimbe bark with ultra-performance liquid chromatography coupled with ion mobility quadrupole time-of-flight mass spectrometry".Rapid Communications in Mass Spectrometry.25 (18):2591–602.Bibcode:2011RCMS...25.2591S.doi:10.1002/rcm.5158.PMID 23657953.
  45. ^Rao MR, Palada MC, Becker BN (2013). "Medicinal and aromatic plants in agroforestry systems". In Nain PK, Rao MR, Buck LE (eds.).New Vistas in Agroforestry: A Compendium for the 1st World Congress of Agroforestry, 2004. Vol. 1. Springer Science and Business Media. p. 109.ISBN 978-94-017-2424-1.
  46. ^Sunderland TC, Ngo-Mpeck M, Tchoundjeu Z, Laird SA (2002). "Yohimbe (Pausinstalia johimbe)". In Shanley P, Pierce AR, Laird SA, Guillén A (eds.).Tapping the Green Market: Certification & Management of Non-Timber Forest Products. Earthscan Publications Ltd. pp. 215–224.ISBN 978-1-85383-871-2.
  47. ^"Quebracho" is formed from the Spanish words for "axe breaker'.
  48. ^Bucher EH (2012). "Chaco and Caatinga — South American Arid Savannas, Woodlands and Thickets". In Huntley BJ, Walker BH (eds.).Ecology of Tropical Savannas. Ecological Studies. Vol. 42. Springer Science and Business. Media. pp. 54–57.ISBN 978-3-642-68786-0.
  49. ^"Nombre científico: Aspidosperma quebracho-blanco".Herbario Digital (in Spanish). CONICET. Retrieved12 January 2019.[dead link]
  50. ^abMoglia JG, López CR (2001)."Variabilidad radial de algunos caracteres anatómicos deAspidosperma quebracho blanco" [Radial variability of some anatomical characters of Aspidosperma white quebracho].Bosque (in Spanish).22 (2): 4.doi:10.4206/bosque.2001.v22n2-01.ISSN 0304-8799.
  51. ^Kent RB (2006).Latin America: Regions and People. Texts in regional geography. Guilford Press. p. 151.ISBN 978-1-57230-909-8.
  52. ^"The IUCN Red List of Threatened Species". Retrieved12 January 2019.
  53. ^abBarger G, Field E (1915)."Yohimbine (Quebrachine)".Journal of the Chemical Society, Transactions.107: 1025.doi:10.1039/CT9150701025.
  54. ^Allen AH, Sadler SS, Lathrop EC, Mitchell CA (1929).Allen's Commercial Organic Analysis. Philadelphia: P. Blakiston's Son & Co. p. 217.
  55. ^Moyano Navarro B (1942). "Quebrachina y Yohimbina: Efectos Sobre la Corriente de Acción del Corazón".Revista de la Universidad Nacional de Córdoba (in Spanish):369–403.. ('Quebrachine' and 'yohimbine' had different effects on the heart in the dog model; but the suppliers of those reagents were trusted to vouch for their authenticity.)
  56. ^Effler EH, Effler AH (1972). "Ûber die Identitat von Quebrachin und Yohimbin".Chemischer Informationsdienst (in German).4 (14):921–924.
  57. ^Abel G, Bos R, Bowen IH, Chandler RF, Corrigan D, Cubbin IJ, De Smet PA, Pras N, Scheffer JJ, Van Beek TT, Van Uden W, Woerdenbag HJ (2012).Adverse Effects of Herbal Drugs. Vol. 3. Springer Science & Business Media.ISBN 978-3-642-60367-9.
  58. ^Bosker G (1995).Emergency Medicine Therapeutics (2nd ed.). Mosby, Incorporated. p. 342.ISBN 978-0-8151-0992-1.
  59. ^Philippsborn H (2006).Elsevier's Dictionary of Vitamins and Pharmacochemistry. Elsevier. p. 599.ISBN 978-0-08-048879-0.
  60. ^Staff (1983).Food and Drug Administration Consumer. U.S. Department of Health, Education, and Welfare, Public Health Service, Food and Drug Administration. p. 10.
  61. ^Lewis RA, Hawley GG (2016). Larrañaga MD, Lewis RJ, Lewis R (eds.).Hawley's Condensed Chemical Dictionary. John Wiley & Sons. p. 1438.ISBN 978-1-118-13515-0.
  62. ^Jeske AH, ed. (2013).Mosby's Dental Drug Reference - E-Book (11th ed.). Elsevier Health Sciences. pp. Appendix H, e83.ISBN 978-0-323-17226-4.
  63. ^Manske RH, Meurant G (1965).The Alkaloids: Chemistry and Physiology. Vol. 8. Academic Press. p. 696.ISBN 978-0-08-086532-4.
  64. ^Riviere JE, Papich MG, eds. (2013).Veterinary Pharmacology and Therapeutics (9th ed.). John Wiley & Sons. p. 353.ISBN 978-1-118-68590-7.
  65. ^Yeung AY, Foster S (2003).Encyclopedia of Common Natural Ingredients: Used in Food, Drugs, and Cosmetics (2nd ed.). Wiley. p. 431.ISBN 978-0-471-47128-8..
  66. ^Hammouda Y, Janot MM, Le Men J (May 1956). "[Presence of yohimbine (quebrachin) in the roots of Madagascar periwinkle, Lochnera lancea]".Annales Pharmaceutiques Françaises (in French).14 (5):341–4.PMID 13373134.
  67. ^"Pausinystalia johimbe".Kew World Checklist of Selected Plant Families.
  68. ^Year Book of the American Pharmaceutical Association. American Pharmaceutical Association. 1914. p. 564. Retrieved20 December 2024.
  69. ^Witkop B (1943). "Zur Konstitution des Yohimbins und seiner Abbauprodukte" [On the constitution of yohimbine and its breakdown products].Justus Liebig's Annalen der Chemie (in German).554 (1):83–126.doi:10.1002/jlac.19435540108.
  70. ^The Alkaloids: Chemistry and Pharmacology. Vol. 32. Academic Press. 1988. p. 564.ISBN 978-0-12-469532-0.
  71. ^van Tamelen E, Shamma M, Burgstahler A, Tamm R, Aldrich P (1958). "The Total Synthesis of Yohimbine".J. Am. Chem. Soc.80 (18):5006–5007.Bibcode:1958JAChS..80.5006V.doi:10.1021/ja01551a062.
  72. ^Herlé B, Wanner MJ, van Maarseveen JH, Hiemstra H (November 2011). "Total synthesis of (+)-yohimbine via an enantioselective organocatalytic Pictet-Spengler reaction".The Journal of Organic Chemistry.76 (21):8907–12.doi:10.1021/jo201657n.PMID 21950549.
  73. ^Seethe Mohadanni case.
  74. ^U.S. Anti-Doping Agency Supplement Guide, p. 28.
  75. ^Doping substances in dietary supplements
  76. ^Singewald N, Schmuckermair C, Whittle N, Holmes A, Ressler KJ (May 2015)."Pharmacology of cognitive enhancers for exposure-based therapy of fear, anxiety and trauma-related disorders". Review.Pharmacology & Therapeutics.149:150–90.doi:10.1016/j.pharmthera.2014.12.004.PMC 4380664.PMID 25550231.
  77. ^McGuire JF, Lewin AB, Storch EA (August 2014)."Enhancing exposure therapy for anxiety disorders, obsessive-compulsive disorder and post-traumatic stress disorder". Review.Expert Review of Neurotherapeutics.14 (8):893–910.doi:10.1586/14737175.2014.934677.PMC 4125602.PMID 24972729.
  78. ^van der Kolk BA (1995)."The Treatment of Post Traumatic Stress Disorder". In Hobfoll SE, De Vries MW (eds.).Extreme stress and communities: impact and intervention. Boston: Kluwer Academic Publishers. pp. 421–44.ISBN 978-0-7923-3468-2.
  79. ^Dimaio Knych HK, Steffey EP, Stanley SD (August 2011). "Pharmacokinetics and pharmacodynamics of three intravenous doses of yohimbine in the horse".Journal of Veterinary Pharmacology and Therapeutics.34 (4):359–366.doi:10.1111/j.1365-2885.2010.01234.x.PMID 20950351.

External links

[edit]
  • "Yohimbine".Drug Information Portal. U.S. National Library of Medicine. Archived fromthe original on June 28, 2019.
Forerectile dysfunction
Prostaglandins (E)
PDE5 inhibitors
Alpha blockers
Dopamine agonists
Melanocortin agonists
Others
Forpremature ejaculation
SSRIs
Oxytocin antagonists
DRA/DRIs
Adamantanes
Adenosine antagonists
Alkylamines
Ampakines
Arylcyclohexylamines
Benzazepines
Cathinones
Cholinergics
Convulsants
Eugeroics
Oxazolines
Phenethylamines
Phenylmorpholines
Piperazines
Piperidines
Phenethylpyrrolidines
Racetams
Psychedelics
Tropanes
Tryptamines
Others
α1
Agonists
Antagonists
α2
Agonists
Antagonists
β
Agonists
Antagonists
5-HT1
5-HT1A
5-HT1B
5-HT1D
5-HT1E
5-HT1F
5-HT2
5-HT2A
5-HT2B
5-HT2C
5-HT37
5-HT3
5-HT4
5-HT5A
5-HT6
5-HT7
Tryptamines
4-Hydroxytryptamines
andesters/ethers
5-Hydroxy- and
5-methoxytryptamines
N-Acetyltryptamines
α-Alkyltryptamines
Cyclized tryptamines
Isotryptamines
Related compounds
Portal:
Retrieved from "https://en.wikipedia.org/w/index.php?title=Yohimbine&oldid=1318227674"
Categories:
Hidden categories:

[8]ページ先頭

©2009-2025 Movatter.jp